Evidence map›Paper›PMID 34232982›Full record

ArticleBlood2021

Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.

Alberto Herrera, Anthony Cheng, Eleni P Mimitou, Angelina Seffens, Dean George, Michal Bar-Natan, Adriana Heguy, Kelly V Ruggles, Jose U Scher, Kenneth Hymes and 8 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07781449 (An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma), which is not on this map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07781449 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma

TypeinterventionalSponsorAarhus University HospitalRan2026 to 2030Enrolled15ConditionsMycosis Fungoides, Cutaneous T-cell LymphomaArmsdelgocitinib
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 3 countries.

Alberto HerreraDepartment of Pathology, New York University School of Medicine, New York, NY.ORCID 0000-0003-4189-9051
Anthony ChengDepartment of Genetic and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT.ORCID 0000-0002-0778-8238
Eleni P MimitouTechnology Innovation Laboratory, New York Genome Center, New York, NY.ORCID 0000-0001-9737-6394
Angelina SeffensDepartment of Pathology, New York University School of Medicine, New York, NY.ORCID 0000-0001-5703-5472
Dean GeorgeDepartment of Dermatology, Boston University and Roger Williams Medical Center, Brown University, Providence, RI.
Michal Bar-NatanDepartment of Pathology, New York University School of Medicine, New York, NY.
Adriana HeguyDepartment of Pathology, New York University School of Medicine, New York, NY.
Kelly V RugglesDivision of Translational Medicine.ORCID 0000-0002-0152-0863
Jose U ScherDivision of Rheumatology, Department of Medicine.ORCID 0000-0002-1072-6994
Kenneth HymesDivision of Hematology/Oncology, and.
Jo-Ann LatkowskiDepartment of Dermatology, New York University School of Medicine, New York, NY.
Niels ØdumLEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-3135-5624
Marshall E KadinDepartment of Dermatology, Boston University and Roger Williams Medical Center, Brown University, Providence, RI.
Zhengqing OuyangDepartment of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA.ORCID 0000-0003-2842-8503
Larisa J GeskinDepartment of Dermatology, Columbia University, New York, NY.
Peter SmibertTechnology Innovation Laboratory, New York Genome Center, New York, NY.ORCID 0000-0003-0772-1647
Terkild B BuusDepartment of Pathology, New York University School of Medicine, New York, NY.ORCID 0000-0001-7180-6384
Sergei B KoralovDepartment of Pathology, New York University School of Medicine, New York, NY.ORCID 0000-0002-4843-3791
New York University · USNew York Genome Center · USRoger Williams Medical Center · USUniversity of Copenhagen · DKCenter for Rheumatology · USCenter for Translational Molecular Medicine · NLColumbia University · USPalmetto Hematology Oncology · USUniversity of Connecticut · USUniversity of Massachusetts Amherst · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Microbial triggers and molecular mechanisms of Th17 mediated airway inflammation-Resubmission-1R01HL125816 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KORALOV, SERGEI BORISOVICH · 2015 to 2019
$3.3M
Massively Parallel Multi-Modal Single-Cell Phenotyping Using a Portable DeviceR21HG009748 · NHGRI · NEW YORK GENOME CENTER · PI SMIBERT, PETER · 2017 to 2019
$754k
NCI NIH HHS P30 CA016087NHGRI NIH HHS R21 HG009748NHLBI NIH HHS R01 HL125816
6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of mature T-cell neoplasms characterized by the accumulation of clonal malignant CD4+ T cells in the skin. The most common variant of CTCL, mycosis fungoides (MF ), is confined to the skin in early stages but can be accompanied by extracutaneous dissemination of malignant T cells to the blood and lymph nodes in advanced stages of disease. Sézary syndrome (SS), a leukemic form of disease, is characterized by significant blood involvement. Little is known about the transcriptional and genomic relationship between skin- and blood-residing malignant T cells in CTCL. To identify and interrogate malignant clones in matched skin and blood from patients with leukemic MF and SS, we combine T-cell receptor clonotyping with quantification of gene expression and cell surface markers at the single cell level. Our data reveal clonal evolution at a transcriptional and genetic level within the malignant populations of individual patients. We highlight highly consistent transcriptional signatures delineating skin- and blood-derived malignant T cells. Analysis of these 2 populations suggests that environmental cues, along with genetic aberrations, contribute to transcriptional profiles of malignant T cells. Our findings indicate that the skin microenvironment in CTCL promotes a transcriptional response supporting rapid malignant expansion, as opposed to the quiescent state observed in the blood, potentially influencing efficacy of therapies. These results provide insight into tissue-specific characteristics of cancerous cells and underscore the need to address the patients' individual malignant profiles at the time of therapy to eliminate all subclones.

Indexed as

Cells, CulturedHumansLymphoma, T-Cell, CutaneousSingle-Cell AnalysisSkin NeoplasmsTranscriptomeTumor Cells, Cultured

Identifiers

PMID34232982
PMCPMC8532199
OpenAlexW3178455046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.